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Regulates Different Inflammatory Mediators Compared 
to Tumor Necrosis Factor in a Model of Psoriatic Arthritis 
Synovitis
Xiaofei Xu,1 Nadine Davelaar,1 Anne-Marie Mus,1 Patrick S. Asmawidjaja,1 Johanna M. W. Hazes,1  
Dominique L. P. Baeten,2 Marijn Vis,1 Radjesh J. Bisoendial,1 Errol P. Prens,1 and Erik Lubberts1
Objective. Interleukin- 17A (IL- 17A) and tumor necrosis factor (TNF) contribute to the pathogenesis of psoriatic 
arthritis (PsA). However, their functional relationship in PsA synovitis has not been fully elucidated. Additionally, 
although CD8+ T cells in PsA have been recognized via flow cytometry as a source of IL- 17A production, it is not 
clear whether CD8+ T cells secrete IL- 17A under more physiologically relevant conditions in the context from PsA 
synovitis. This study was undertaken to clarify the roles of IL- 17A and TNF in the synovial fluid (SF) from patients with 
PsA and investigate the impact of CD8+ T cells on IL- 17A production.
Methods. IL- 17A+ T cells were identified by flow cytometry in SF samples from 20 patients with active PsA, blood 
samples from 22 treatment- naive patients with PsA, and blood samples from 22 healthy donors. IL- 17A+ T cells were 
sorted from 12 PsA SF samples and stimulated using anti- CD3/anti- CD28 or phorbol myristate acetate (PMA) and 
ionomycin ex vivo, alone (n = 3) or together with autologous monocytes (n = 3) or PsA fibroblast- like synoviocytes 
(FLS) (n = 5–6). To evaluate the differential allogeneic effects of neutralizing IL- 17A and TNF, SF CD4+ T cells and PsA 
FLS cocultures were also used (n = 5–6).
Results. Flow cytometry analyses of SF samples from patients with PsA showed IL-17A positivity for CD4+ and 
CD8+ T cells (IL- 17A, median 0.71% [interquartile range 0.35–1.50%] in CD4+ cells; median 0.44% [interquartile 
range 0.17–1.86%] in CD8+ T cells).
However, only CD4+ T cells secreted IL- 17A after anti- CD3/anti- CD28 activation, when cultured alone and in 
cocultures with PsA monocytes or PsA FLS (each P < 0.05). Remarkably, CD8+ T cells only secreted IL- 17A after 4- or 
72- hour stimulation with PMA/ionomycin. Anti–IL- 17A and anti- TNF treatments both inhibited PsA synovitis ex vivo. 
Neutralizing IL- 17A strongly inhibited IL- 6 (P < 0.05) and IL- 1β (P < 0.01), while anti- TNF treatment was more potent 
in reducing matrix metalloproteinase 3 (MMP- 3) (P < 0.05) and MMP- 13. 
Conclusion. CD8+ T cells, in contrast to CD4+ T cells, in SF specimens obtained from PsA patients did not 
secrete IL- 17A following T cell receptor activation. Overlapping, but distinct, effects at the level of inflammatory 
cytokines and MMPs were found after neutralizing IL- 17A or TNF ex vivo in a human model of PsA synovitis.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that 
develops in up to 30% of patients with active psoriasis or a his-
tory of psoriasis (1). Activated T cells have long been reported 
to contribute to arthropathies, including PsA pathogenesis (2), 
and therapies that deplete lymphocytes have been tested in PsA 
patients with limited clinical response (3), with lack of efficacy dur-
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ing depletion therapy attributed to the presence of modest lym-
phopenia in the synovial fluid (SF) despite a significant reduction 
in lymphocytes in the peripheral blood. This pinpoints the patho-
genic role of local T cells in PsA joints. Moreover, enhanced local 
clonal expansions of CD4+ and CD8+ T cells were identified in 
PsA SF compared to PsA peripheral blood (4), further suggesting 
that intraarticular T cell activation drives PsA joint inflammation.
Activated T cells excrete a wide range of proinflammatory 
cytokines including interleukin- 17A (IL- 17A) and tumor necrosis 
factor (TNF), both of which have been shown to be elevated in 
PsA SF or synovium (5–7). Evidence from studies of PsA patients 
and other arthropathies points to the involvement of IL- 17A in the 
pathogenesis of arthritis (8,9). It has been suggested that CD4+ T 
cells (10,11), CD8+ T cells (12–14), and group 3 innate lymphoid 
cells (ILCs) (15) can be potential sources of IL- 17A in PsA SF or 
synovium. However, it is still not clear which of the above cell types 
is the main producer of IL- 17A in local joints affected with PsA. 
Recently, it was reported that ILC3s fail to express IL- 17A upon 
in vitro stimulation in joints affected with spondyloarthritis (16). 
Nevertheless, direct ex vivo comparison of IL- 17A production 
upon T cell receptor (TCR) activation by CD4+ and CD8+ T cells 
has yet to be performed using PsA SF specimens.
TNF is a proinflammatory cytokine present at high levels in 
PsA (5,6). Neutralization of TNF has been proven to be effective in 
reducing local inflammation while slowing or halting joint destruc-
tion in individuals with PsA (17). However, with success rates of 
~60–70% in patients with active PsA, standard anti- TNF therapies 
fail to achieve satisfactory results in the remaining nonresponders 
(18,19). Even among responders, initial efficacy with TNF inhibition 
fails to sustain a response in some subgroups of patients (18). 
Interestingly, in psoriasis patients who are not responsive to the 
TNF blocker, etanercept, persistent serum levels of IL- 17A were 
observed (20). Recent studies have shown that antibodies target-
ing IL- 17A, including secukinumab and ixekizumab, were effective 
in treating PsA patients (21,22), and both have been approved 
for treatment of active PsA. Similar to anti- TNF biologic agents, 
IL- 17A blockade also successfully suppresses joint inflammation 
and prevents radiographic progression (21,22). Patients intolerant 
or nonresponsive to TNF inhibition still showed disease improve-
ment with anti–IL- 17A therapy (23,24). Further understanding of 
the potential overlapping and distinct effects of anti–IL- 17A and 
anti- TNF treatments is still relevant, and additional insights may 
help guide clinical practice and potentially lead to achievement 
of more sustainable therapeutic effects for individuals with PsA.
PATIENTS AND METHODS
Study design. IL- 17A+ CD4+ and CD8+ T cells were 
first identified using flow cytometry in the following groups: 
1) SF from patients with active PsA, 2) peripheral blood from 
treatment- naive patients with early PsA, and 3) peripheral blood 
from age- and sex- matched healthy volunteers as controls. 
CD4+ and CD8+ T cells from SF samples were then sorted to 
compare ex vivo IL- 17A secretion in the absence or presence 
of stimulation with anti- CD3/anti- CD28 or phorbol myristate 
acetate (PMA)/ionomycin. Sorted CD4+ and CD8+ T cells were 
further cocultured with autologous PsA monocytes or allogeneic 
PsA fibroblasts to examine ex vivo IL- 17A secretion. With TCR 
activation, sorted SF CD4+ T cells were cocultured with PsA 
fibroblasts to evaluate the effects of IL- 17A neutralization com-
pared to TNF blockade.
Patients. SF samples from 20 patients with active PsA were 
collected. Peripheral blood from 22 treatment- naive patients with 
early PsA and 22 age- and sex- matched healthy volunteers were 
also included in the analysis. PsA was diagnosed by rheumatolo-
gists according to the Classification of Psoriatic Arthritis (CASPAR) 
Study Group criteria (25). This study is part of the Dutch Southwest 
Psoriatic Arthritis Register (DEPAR) and is approved by the Ethics 
Review Board of Erasmus University Medical Center Rotterdam. 
Details on the demographic and clinical characteristics of the PsA 
patients and healthy volunteers are summarized in Supplemen-
tary Table 1, available on the Arthritis & Rheumatology website 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41271/ abstract.
Flow cytometry and cell sorting. Cell pellets from PsA 
SF samples were stained for surface markers with or without 
density gradient centrifugation in accordance with standard prac-
tice. Peripheral blood from patients with early PsA and healthy 
volunteers were also lysed for red blood cells and stained for 
surface markers in the same manner as described above. For 
intracellular staining, parts of the cell pellets were stimulated for 4 
hours with 50 ng/ml of PMA (Sigma- Aldrich), 500 ng/ml of iono-
mycin, and GolgiStop (BD Biosciences). Cells were then stained 
for surface markers and Fixable Viability Dye eF506 (eBioscience 
no. 65- 0866- 14) according to the manufacturer’s instructions. 
Cells were then fixed with 2% paraformaldehyde in phosphate 
buffered saline (PBS) and permeabilized with 0.5% saponin buffer 
(0.5% bovine serum albumin, 0.05% NaN3 in PBS).
Sorted CD4+ and CD8+ T cells were cultured or cocultured 
ex vivo for 72 hours and restimulated to examine intracellular 
staining as described above. An LSRII flow cytometer (BD Bio-
sciences) was used to analyze samples, and results were pro-
cessed with FlowJo software (TreeStar). Cells were sorted with a 
FACSAria cell sorter (BD Biosciences), and the purity of the sorted 
cell populations was found to be ≥98%.
Flow cytometry antibodies. The following antibodies 
were used during staining: phycoerythrin (PE)–CF594–conjugated 
CD8 (clone RPA- T8; BD Biosciences), PE–Cy7–conjugated TCRγδ 
(clone 11F2; BD Biosciences), PE–Cy7–conjugated CD19 (clone 
SJ25C1; BD Biosciences), PE–CF594–conjugated CD45 (clone 
HI30; BD Biosciences), allophycocyanin (APC)–H7–conjugated 
CD14 (clone MϕP9; BD Biosciences), PerCP–Cy5.5–conjugated 
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CD45RO (clone UCHL1; BD Biosciences), Alexa Fluor 700– 
conjugated CD56 (clone 5.1H11; BioLegend), Alexa Fluor 
700–conjugated CD15 (clone W6D3; BioLegend), BV785- 
conjugated CD16 (clone 3G8; BioLegend), Alexa Fluor 488–
conjugated interferon- γ (IFNγ) (clone 4S.B3; BioLegend), 
BV421- conjugated TNF (clone MAb11; BioLegend), PE–Cy7–
conjugated CD25 (clone BC96; BioLegend), PE- conjugated IL- 
17A (clone eBio64DEC17; eBioscience), eF660- conjugated IL- 22 
(clone 22URTI; eBioscience), PerCP–Cy5.5–conjugated CD45 
(clone HI30; Sony Biotechnology), BV785- conjugated CD3 (clone 
OKT3; Sony Biotechnology), BV711- conjugated CD4 (clone 
OKT4; Sony Biotechnology), and fluorescein isothiocyanate–con-
jugated CD4 (clone RPA- T4; Sony Biotechnology).
Cell culture. Sorted T cells were seeded at 2.5 × 104/well 
in 96- well round- bottomed culture plates and stimulated with 
0.3 μg/ml of soluble anti- CD3 (Sanquin) and 0.4 μg/ml of soluble 
anti- CD28 (Sanquin) for 4 hours or 72 hours in Iscove’s modified 
Dulbecco’s medium (Lonza) supplemented with 10% fetal calf 
serum (Invitrogen), 100 units/ml penicillin/streptomycin (Lonza), 
2 mM l- glutamine (Lonza), and 50 μM β- mercaptoethanol 
(Merck). PsA fibroblast- like synoviocytes (FLS) were isolated and 
cultured as described previously (26). After reaching 90% conflu-
ence, allogeneic PsA FLS were seeded at 1.0 × 104/well in 96- 
well flat- bottomed culture plates, and after overnight incubation, 
T cells were added at 2.5 × 104/well following incubation with 
soluble anti- CD3/anti- CD28 for 72 hours as described above. 
In cocultures with autologous monocytes, CD14+ monocytes at 
1.0 × 104/well were seeded with T cells at 2.5 × 104/well in 96- 
well round- bottomed culture plates and incubated with soluble 
anti- CD3/anti- CD28 for 72 hours.
During neutralization experiments, 100 μg/ml of anti–IL- 17 
(secukinumab; Novartis) and 1 μg/ml of anti- TNF (adalimumab; 
AbbVie) were used. An isotype (IgG1κ; Sigma- Aldrich) was 
included as control, and soluble anti- CD3/anti- CD28 activation 
was used as stimulation.
Enzyme- linked immunosorbent assay (ELISA). IFNγ, 
IL- 6, and IL- 8 in culture supernatants were measured by ELISA 
(Invitrogen) according to the manufacturer’s instructions. IL- 17A, 
TNF, matrix metalloproteinase 1 (MMP- 1), and MMP- 3 were mea-
sured with ELISA DuoSet (R&D Systems) according to the manu-
facturer’s instructions.
Real- time reverse transcription–polymerase chain 
reaction (RT- PCR). RNA was isolated with a Total RNA Mini-
prep Kit (Sigma- Aldrich). Complementary DNA was synthesized 
with 10 units/μl of Superscript II (Invitrogen) following treatment 
with 0.1 units/μl of DNAse (Invitrogen). RT- PCR was performed 
with a ViiA 7 Sequence Detecting System (Life Technologies). 
Probes were chosen from the universal probe library (Roche 
Applied Science), and primers were designed using ProbeFinder 
software. Gene expression data were normalized to the expres-
sion values for the housekeeping gene hypoxanthine guanine 
phosphoribosyltransferase (HPRT). Primer sequences are avail-
able upon request from the corresponding author.
Statistical analysis. Flow cytometry results are shown as 
the median (interquartile range [IQR]), and ex vivo stimulation data 
are shown as the mean ± SEM. Statistical differences were deter-
mined with Student’s paired or unpaired t- test. All data analyses 
were performed with GraphPad Prism software version 5.0. P val-
ues less than 0.05 were considered significant.
RESULTS
Comparable subsets of lymphoid and myeloid cells, 
but not B cells or natural killer (NK) cells, in PsA SF and 
peripheral blood. Peripheral blood samples from patients with 
early PsA and matched healthy volunteers (n = 22 each) as well 
as SF samples from patients with active PsA (n = 20) were stained 
for surface markers to identify immune cells. Gating strategies for 
cell populations are shown in Supplementary Figure 1, available 
on the Arthritis & Rheumatology website at http://onlin elibr ary.
wiley.com/doi/10.1002/art.41271/ abstract. The median percent-
ages of CD3+ T cells were 44.8% (IQR 8.6–55.4%) in SF from 
PsA patients, 43.3% (IQR 25.6–58.2%) in peripheral blood from 
PsA patients, and 47.5% (IQR 26.7–60.3%) in blood from healthy 
controls  (Figure 1A). For myeloid cells, the median percentages 
of CD14+ monocytes in SF from PsA patients, peripheral blood 
from PsA patients, and peripheral blood from healthy controls 
were 6.2% (IQR 2.4–9.7%), 5.2% (IQR 2.7–9.9%), and 6.2% (IQR 
3.7–9.9%), respectively. Median percentages of CD15+CD16+ 
neutrophils in SF from PsA patients, peripheral blood from PsA 
patients, and peripheral blood from healthy controls were 22.8% 
(IQR 4.3–38.3%), median 17.3% (IQR 3.3–50.4%), and median 
10.2% (IQR 3.1–40.6%), respectively (Figure 1A).
Among CD3+ T cell subsets, the median percentages of 
CD4+ T cells accounted for >60% of the T cell population (60.5% 
[IQR 52.7–69.9%] in SF from PsA patients, 64.6% [IQR 57.1–
71.7%] in peripheral blood from PsA patients, and 66.2% [IQR 
56.5–1.6] in peripheral blood from healthy controls) (Figure 1B). 
Approximately 30% of total T cells were CD8+ cells (median 
31.3% [IQR 22.6–40.3%]) in SF from PsA patients, median 
29.7% [IQR 23.5–35.8%] in peripheral blood from PsA patients, 
and median 26.7% [21.9–38.2%] in peripheral blood from healthy 
controls (Figure 1B). Median percentages of TCRγδ+ T cells were 
~1.5–2.5% among all groups (1.4% [IQR 0.92–2.7%] in SF from 
PsA patients, 1.7% [IQR 0.99–2.8%] in peripheral blood from 
PsA patients, and 2.3% [IQR 1.7–3.7%] in peripheral blood from 
healthy controls) (Figure 1B).
As shown in Figure 1C, significantly enhanced accumulation 
of CD56bright NK cells in the SF from PsA patients was observed 
when compared to peripheral blood from either treatment- naive 
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patients with early PsA or healthy controls (median 1.62% [IQR 
0.64–2.62%] in SF from PsA patients compared to median 
0.24% [IQR 0.13–0.69%] in peripheral blood from PsA patients 
and median 0.39% [IQR 0.20–0.56%] in peripheral blood from 
healthy controls). In contrast, the median percentages of CD19+ 
B cells in SF from PsA patients were significantly lower compared 
to either blood samples, with 0.17% (IQR 0.08–0.30%) in SF from 
PsA patients, 3.38% (IQR 2.65–7.71%) in peripheral blood from 
PsA patients, and 5.26% (IQR 2.05–6.87%) in peripheral blood 
from healthy controls (Figure 1C).
Enrichment of IL- 17A+CD8+ T cells in PsA SF com-
pared to peripheral blood. Cell pellets from the SF from 
patients with active PsA (n = 20) and peripheral blood from 
treatment- naive patients with early PsA and healthy volunteers 
(n = 22 each) were intracellularly stained for IL- 17A, IFNγ, TNF, 
and IL- 22. Intracellular staining showed that surface marker CD4, 
but not CD8, was down- regulated in the PsA SF following stim-
ulation with PMA and ionomycin (Supplementary Figure 2, avail-
able on the Arthritis & Rheumatology website at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41271/ abstract). Therefore, the 
CD45+CD3+CD8− T cell population was considered as CD4+ T 
cells. In Figure 2A, representative results of intracellular staining 
for IL- 17A, IFNγ, TNF, and IL- 22 among CD4+ and CD8+ T cells 
in SF from PsA patients, peripheral blood from PsA patients, and 
peripheral blood from healthy volunteers are shown.
In PsA SF samples, the median percentages of IL- 17A 
expression were not significantly different between CD4+ and 
CD8+ T cells (in CD4+ T cells, median 0.71% [IQR 0.35–1.50%]; 
in CD8+ T cells, median 0.44% [IQR 0.17–1.86%]) (Figure 2B). 
In peripheral blood from PsA patients, however, the median per-
centages of IL- 17A expression were significantly lower in CD8+ T 
cells than in CD4+ T cells (in CD8+ T cells, median 0.13% [IQR 
0.09–0.22%]; in CD4+ T cells, median 0.95% [IQR 0.77–1.36%]) 
(Figure 2B). A similar result with regard to IL- 17A expression within 
the T cell subsets was found in the peripheral blood from healthy 
controls (in CD4+ T cells, median 1.15% [IQR 0.73–1.78%]; in 
CD8+ T cells, median 0.13% [IQR 0.08–0.21%]) (Figure 2B).
In the SF from patients PsA, the percentage of IFNγ+ CD8+ 
T cells was significantly higher than the percentage of IFNγ+ 
CD4+ T cells. In PsA SF, the median proportion of IFNγ+ cells 
among CD4+ T cells was 44.4% (IQR 24.7–64.8%) compared to 
Figure 1. Differences in the percentages of B cells and natural killer (NK) cells in synovial fluid (SF) from patients with psoriatic arthritis (PsA) 
compared to peripheral blood from PsA patients and healthy controls. SF samples from 20 patients with active PsA and peripheral blood 
samples from 22 patients with early PsA and 22 age- and sex- matched healthy volunteers were stained for surface markers. Gating strategies 
for cell populations are shown in Supplementary Figure 1, available on the Arthritis & Rheumatology website at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41271/ abstract. A, Frequency of T cells (CD3+), myeloid cells (CD14+ monocytes), and neutrophils (CD15+CD16+) among 
CD45+ immune cells. B, CD4+, CD8+, and T cell receptor γδ (TCRγδ) T cell subsets among CD3+ immune cells. C, Levels of NK cells (CD3–
CD56bright) and B cells (CD3−CD19+) among CD45+ immune cells. Symbols represent individual samples; horizontal lines and error bars show 
the median and interquartile range. *** = P < 0.001.
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a median proportion of IFNγ+ cells among CD4+ T cells of 28.8% 
(IQR 13.5–41.2%). Similar differences were observed in periph-
eral blood samples from PsA patients in regard to the percent-
age of IFNγ+CD4+ cells (median 13.1% [IQR 10.0–15.2%]) 
compared to the percentage of IFNγ+CD8+ cells (median 36.4% 
[IQR 20.3–47.2%]) as well as in peripheral blood from healthy 
controls (median 17.6% [IQR 13.3–22.2%] for IFNγ+CD4+ cells 
versus median 42.1% [IQR 34.0–72.0%] for IFNγ+CD8+ cells) 
(Figure 2B).
In the SF from PsA patients, the median percentage of 
TNF+CD4+ T cells was significantly higher than percentage of 
TNF+CD8+ T cells (for CD4+ T cells, median 15.7% [IQR 5.8–
22.7%]; for CD8+ T cells, 6.5% [IQR 3.4–12.1%]) (Figure 2B). 
However, findings were similar in the peripheral blood from PsA 
patients (median 12.5% [IQR 5.3–17.4%] for TNF+CD4+ T cells 
versus median 5.9% [IQR 3.5–17.9%] for TNF+CD8+ T cells) 
and in the peripheral blood from healthy controls (median 16.5% 
[IQR 9.9–20.1%] for TNF+CD4+ T cells versus median 16.2% 
[IQR 9.1–22.0%] for TNF+CD8+ T cells) (Figure 2B).
With regard to IL- 22+ cells, the proportion of IL- 22+CD4+ 
T cells was higher than the proportion of IL- 22+CD8+ T cells in 
the SF from patients with PsA (median 0.61% [IQR 0.26–1.74%] 
for IL-22+CD4+ T cells median 0.20 [IQR 0.06–0.38%] for 
IL-22+CD8+ T cells) (Figure 2B). Similar findings were observed in 
the peripheral blood from PsA patients, with the median percent-
ages of IL-22+CD4+ T cells and IL-22+CD8+ T cells differing sig-
nificantly (median 1.35% [IQR 0.96–1.82%] for IL-22+CD4+ T cells 
versus median 0.27% [IQR 0.16–0.32%] for IL-22+CD8+ T cells) 
Figure 2. Enrichment of interleukin- 17A+ (IL- 17A+) CD8+ T cells in synovial fluid (SF) samples from patients with psoriatic arthritis (PsA) 
compared to peripheral blood (PB) samples. A, Representative intracellular staining for IL- 17A, interferon- γ (IFNγ), tumor necrosis factor (TNF), 
and IL- 22 among SF samples from PsA patients (n = 20), peripheral blood samples from PsA patients (n = 22), and peripheral blood samples 
from healthy controls (n = 22) after 4 hours of stimulation with phorbol myristate acetate/ionomycin. B, IL- 17A, IFNγ, TNF, and IL- 22 staining of 
CD4+ T cells and CD8+ T cells in PsA SF (left) and peripheral blood (right). C, Percentage ratios of CD8+ T cells to CD4+ T cells summarized 
for each cytokine staining in individual samples. Symbols represent individual samples; horizontal lines and error bars show the median and 
interquartile range. * = P < 0.05; ** = P < 0.01; *** = P < 0.001.
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as well as in the peripheral blood from healthy controls (median 
1.51% [IQR 0.81–2.30%] for IL-22+CD4+ T cells versus median 
0.20% [IQR 0.15–0.34%] for IL-22+CD8+ T cells) (Figure 2B). 
For direct comparison of differences between percentages 
of CD4+ and CD8+ T cells in SF from PsA patients, peripheral 
blood from PsA patients, and peripheral blood from healthy 
controls, percentage ratios were calculated. The percentage 
of IL- 17A+CD8+ T cells was divided by the percentage of IL- 
17A+CD4+ T cells, with similar calculations performed for IFNγ, 
TNF, and IL- 22 expression between both T cell subsets. Percent-
age ratios close to 1 in PsA SF (median 0.77 [IQR 0.33–1.39]) 
indicated that nearly equal percentages of CD8+ and CD4+ T 
cells were IL- 17A+ (Figure 2C). In contrast, percentage ratios in 
the peripheral blood from PsA patients (median 0.12 [IQR 0.09–
0.30]) and peripheral blood from healthy controls (median 0.11 
[IQR 0.08–0.18]) were both significantly lower than the percent-
age ratios in SF from PsA patients (Figure 2C). This suggests that 
a specific enrichment of IL- 17A+CD8+ T cells over IL- 17A+CD4+ 
T cells in PsA SF compared to peripheral blood from PsA patients 
and healthy controls.
With regard to IFNγ+ cells, the percentage ratios were a 
median 1.72 (IQR 1.34–2.10) in PsA SF, 2.81 (IQR 1.90–3.75) in 
peripheral blood from PsA patients, and 2.67 (IQR 1.59–3.36) in 
peripheral blood from healthy controls (Figure 2C), indicating 2–3 
times more IFNγ+CD8+ T cells than IFNγ+CD4+ T cells in all groups.
TNF+ percentage ratios were comparable between SF from 
PsA patients (0.60 [IQR 0.46–0.71]), peripheral blood from PsA 
patients (0.75 [IQR 0.44–1.21]), and peripheral blood from healthy 
controls (1.02 [IQR 0.72–1.31]) (Figure  2C). This suggests that 
almost equal percentages of CD8+ and CD4+ T cells were TNF+ 
in PsA SF and peripheral blood.
Similar to IL- 17A, median IL- 22+ percentage ratios were sig-
nificantly higher in SF from PsA patients (0.33 [IQR 0.07–1.17]) 
than in peripheral blood from PsA patients (0.17 [IQR 0.14–0.31]) 
and peripheral blood from healthy controls (0.19 [IQR 0.09–0.32]), 
indicating enhanced accumulation of IL- 22+CD8+ T cells when 
compared to IL-22+CD4+ T cells in PsA SF compared to periph-
eral blood from PsA patients and healthy controls.
Secretion of IL- 17A upon TCR activation of CD4+ T 
cells, but not CD8+ T cells, in PsA SF. To compare IL- 17A 
production and secretion between CD4+ and CD8+ T cells, PsA 
SF CD4+ and CD8+ T cells were sorted from SF mononuclear 
cells (SFMCs). These sorted cells were stimulated with anti- CD3/
anti- CD28 and cultured ex vivo for 72 hours. Sorted CD4+ T cells 
did not include CD4+CD14+ monocytes or CD4+CD25high T regu-
latory cells. After 72 hours, the concentration of IL- 17A was meas-
ured in culture supernatants using ELISA. Cells were also assessed 
by intracellular staining for IL- 17A, in which cells were stimulated 
with PMA/ionomycin for another 4 hours. As shown in Figure 3A, 
Figure 3. Production of IL- 17A by CD4+ T cells, but not CD8+ T cells, upon anti- CD3/anti- CD28 activation in PsA SF. A, IL- 17A staining 
in cells and protein level in culture supernatants from sorted CD4+ and CD8+ T cells from SF samples after 72 hours of ex vivo anti- CD3/
anti- CD28 activation. B, IL- 17A staining in cells and protein levels in culture supernatants from SF CD4+ and CD8+ T cells after 72 hours of 
coculture with allogeneic PsA fibroblast- like synoviocytes and anti- CD3/anti- CD28 activation. In A and B, n = 5 or 6 samples per group from 
2 independent experiments. C, IL- 17A in culture supernatants and mRNA expression in SF CD4+ and CD8+ T cells after 72 hours of ex vivo 
coculture with autologous CD14+ monocytes and anti- CD3/anti- CD28 activation (n = 3; different patients assessed than those in A and B). D 
and E, IL- 17A in culture supernatants and mRNA expression in sorted SF CD4+ and CD8+ T cells that were left unstimulated or after ex vivo 
stimulation with anti- CD3/anti- CD28 or phorbol myristate acetate/ionomycin (PMA/ion), after 72 hours (n = 3; different patients assessed than 
those in A and B) (broken line indicates IL- 17A detection limit) (D) and IL- 17A in culture supernatants subjected to the same culture conditions 
as in D for 4 hours (n = 3) (E). Values are the mean ± SEM. * = P < 0.05. See Figure 2 for other definitions.
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intracellular staining for IL- 17A was positive in both CD4+ and 
CD8+ T cells. However, in contrast to the results of intracellular IL- 
17A staining, measurement of IL- 17A secretion in the supernatants 
showed that IL- 17A was only secreted by CD4+ T cells, but not 
CD8+ T cells. Similar results were observed for IL- 17F, as shown in 
Supplementary Figure 3, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41271/ 
abstract.
To further confirm that anti- CD3/anti- CD28 activation did not 
result in secretion of IL- 17A from CD8+ T cells, CD4+ and CD8+ 
T cells were sorted from PsA SFMCs and cocultured with alloge-
neic PsA FLS or autologous CD14+ PsA monocytes. Consistent 
with the findings described above, flow cytometry revealed that 
CD8+ T cells stained positive for IL- 17A after 3 days of coculture 
with PsA FLS (Figure 3B). However, excreted IL- 17A levels were 
not detectable in supernatants of anti- CD3/anti- CD28–activated 
CD8+ T cell cocultures with PSA FLS (Figure  3B). Similarly, in 
CD4+ and CD8+ T cells that were cocultured for 72 hours with 
autologous monocytes, anti- CD3/anti- CD28 activation led to IL- 
17A secretion in coculture supernatants and expression of IL- 
17A messenger RNA (mRNA) only in CD4+ T cells, but not in 
CD8+ T cells (Figure 3C).
To further investigate this discrepancy, PsA SF CD4+ and 
CD8+ T cells were cultured with anti- CD3/anti- CD28 or PMA/ion-
omycin, or left unstimulated, for 4 hours and 72 hours. As shown 
in Figure 3D, at 72 hours, only CD4+ T cells produced IL- 17A 
after anti- CD3/anti- CD28 activation at both protein and mRNA 
levels, while PMA/ionomycin stimulated both CD4+ and CD8+ 
T cells to produce IL- 17A. Similar results were confirmed with 
72- hour cocultures of T cells and autologous monocytes (Sup-
plementary Figure 4, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41271/ 
Figure 4. Induction of differential effects by IL- 17A compared to TNF in PsA fibroblast- like synoviocytes (FLS). CD4+ T cells were sorted from PsA SF 
and cocultured with allogeneic PsA FLS for 72 hours in the absence or presence of anti- CD3/anti- CD28 stimulation. A, Reduced levels of IL- 17A and 
TNF, but not IFNγ, with anti–IL- 17A and anti- TNF treatment compared to treatment with isotype control antibody, in culture supernatants of cocultured 
cells. B, IL- 6 and IL- 8 levels in culture supernatants and IL- 1β mRNA expression levels in cocultured cells after 72 hours. Levels of IL- 8 were significantly 
reduced by both anti–IL- 17A and anti- TNF treatments compared to treatment with isotype antibody. IL- 6 production was significantly reduced by 
anti–IL- 17A therapy compared to both isotype control and anti- TNF therapy. Anti- TNF treatment significantly reduced expression of mRNA for IL- 
1β, though it was significantly less effective compared to anti–IL- 17A treatment. C, Matrix metalloproteinase 1 (MMP- 1) and MMP- 3 levels in culture 
supernatants and MMP- 9 and MMP- 13 mRNA expression levels in cocultured cells after 72 hours. Levels of MMP- 1 and MMP- 9 were significantly 
down- regulated by the combination treatment of anti–IL- 17A and anti- TNF compared to isotype control or anti–IL- 17A alone. MMP- 3 levels were 
significantly reduced after anti-TNF therapy compared to treatment with anti–IL- 17A or isotype control, and MMP-13 levels were significantly reduced 
after anti-TNF therapy compared to therapy with anti–IL-17A/anti-TNF combination therapy or isotype control. Values are the mean ± SEM of 5 or 6 
samples and are pooled from 2 independent experiments. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. See Figure 2 for other definitions.
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abstract). More importantly, as shown in Figure 3E, even after 
4 hours of PMA/ionomycin stimulation, CD8+ T cells produced 
as much IL- 17A as CD4+ T cells, but no IL- 17A secretion was 
detectable by CD8+ T cells after 4 hours of anti- CD3/anti- CD28 
stimulation. Time course analysis evaluating IL- 17A expression 
in CD4+ and CD8+ T cells at 24, 48, and 72 hours after stimula-
tion with anti- CD3/anti- CD28 or PMA/ionomycin in SF samples 
from 3 other PsA patients confirmed the above findings (data 
not shown).
Overlapping and differential effects of IL-17A–
induced inflammation compared to TNF-induced 
inflammation in PsA FLS. As established above, CD4+ T 
cells in PSA SF are the main IL- 17A producers with anti- CD3/
anti- CD28 activation. To evaluate overlapping and differen-
tial therapeutic effects of TNF and IL- 17A blockers, CD4+ 
T cells were isolated from PsA SFMCs, stimulated with 
anti- CD3/anti- CD28, and cocultured with allogeneic PsA 
FLS. Expression of IL- 17RA and IL- 17RC was confirmed on 
both PsA FLS and CD14+ PsA monocytes (Supplementary Figure 
5, available on the Arthritis & Rheumatology website at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41271/ abstract). As shown in 
Supplementary Figure 6 (available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41271/ 
abstract), pre- titrations of antibodies were performed, and con-
centrations were chosen to comparably achieve 60–70% inhibi-
tion for each cytokine.
Anti–IL- 17A and anti- TNF antibody treatment each specifi-
cally and significantly reduced the production of either IL- 17A or 
TNF, respectively, in the coculture system (Figure 4A). Compared 
to an isotype antibody control, IFNγ was not affected by anti–IL- 
17A and anti- TNF antibody treatment (Figure 4A). Both anti–IL- 
17A and anti- TNF treatments significantly reduced IL- 8 levels 
compared to the isotype antibody group (Figure 4B). Combining 
both antibodies yielded a significant additive effect compared to 
anti–IL- 17A alone (Figure 4B). Interestingly, anti- TNF did not sig-
nificantly influence IL- 6 production in these cocultures compared 
to the isotype control, while anti–IL- 17A significantly suppressed 
the levels of IL- 6 compared to both isotype controls and anti- 
TNF (Figure 4B). Similar results were observed during antibody 
titrations (Supplementary Figure 6, http://onlin elibr ary.wiley.com/
doi/10.1002/art.41271/ abstract). Although anti- TNF treatment 
significantly reduced mRNA expression of IL- 1β, it was significantly 
less effective compared to anti–IL- 17A treatment (Figure 4B).
Levels of MMP- 1 were significantly down- regulated by the 
combination treatment of anti–IL- 17A and anti- TNF compared 
to isotype control or anti–IL- 17A alone (Figure 4C). MMP- 3 levels 
were significantly suppressed after neutralizing TNF compared to 
both anti–IL- 17A and isotype control (Figure 4C). Similar to the 
effects on MMP- 1, expression of MMP- 9 was significantly reduced 
only by the combination of anti–IL- 17A and anti- TNF compared 
to isotype control (Figure 4C). Similar to the effects on MMP- 3, 
anti- TNF treatment significantly down- regulated the expression of 
MMP- 13 compared to isotype control, and in combination with 
anti–IL- 17A, achieved a significant level of further reduction of 
MMP- 13 expression compared to treatment with either antibody 
alone (Figure 4C).
DISCUSSION
Currently, the role of IL- 17A in the pathogenesis of PsA is 
widely accepted following the clinical success of biologic agents 
targeting the IL- 17 pathway (21,22). Though various cell types 
have been suggested to be potential sources of IL- 17A in PsA, 
a detailed ex vivo analysis comparing IL- 17A–producing cells 
using various techniques is still of relevance. Here, we present evi-
dence that CD4+ T cells, but not CD8+ T cells, in the SF from PsA 
patients excrete IL- 17A upon ex vivo activation with anti- CD3/
anti- CD28. This indicates that upon TCR activation, CD4+ T cells 
will be the main producer of IL- 17A in local joints affected with PsA 
despite the fact that both CD4 and CD8 T cells produce IL- 17A 
with PMA and ionomycin stimulation. To better reflect in- tissue 
conditions, SF T cells were cocultured with FLS. With this ex vivo 
PsA coculture assay, we showed that anti–IL- 17A and anti- TNF 
both have therapeutic effects in inhibiting the proinflammatory 
activation loop between T cells and stromal cells. Interestingly, 
differential effects between anti–IL- 17A and anti- TNF were also 
observed. Anti–IL- 17A treatment demonstrates stronger inhibition 
of inflammatory cytokines such as IL- 6 and IL- 1β while anti- TNF 
therapy has a more potent response in reducing the production 
of MMPs.
Earlier reports have suggested that CD8+ T cells are predom-
inant in PsA (27). However, our findings show that CD4+ T cells 
are the major T cell subset in PsA SF, which is similar to PsA blood. 
Possible explanations for this finding may lie in the methods of 
handling samples. First, during our experiments, surface staining 
was performed directly after cell pelleting without density gradi-
ent separation, in order to maintain the T cell subsets in genuine 
conditions resembling those found in vivo. Second, percentages 
of cell subsets were analyzed without stimulation ex vivo and 
separated from intracellular staining. PMA and ionomycin stimu-
lation conventionally used during intracellular staining can strongly 
down- regulate CD4, but not CD8, surface expression, as shown 
in Supplementary Figure 1, available on the Arthritis & Rheuma-
tology website at http://onlin elibr ary.wiley.com/doi/10.1002/art. 
41271/ abstract. Therefore, research conditions should represent 
the infiltrated immune cell characteristics in SF from patients with 
PsA as closely as possible.
IL- 17A+CD8+ T cells have been observed in both psoria-
sis and PsA (12–14,28,29), and particularly in PsA, it was found 
that the percentage of IL- 17A+CD8+ T cells correlates with dis-
ease activity and progression of joint damage (12). Our results 
confirmed the enrichment of IL- 17A+CD8+ T cells in PsA SF. 
However, most of the results from previously published studies 
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on IL- 17A+ were obtained via intracellular staining with PMA and 
ionomycin stimulation (11–14,28,29). Such strong stimuli do not 
resemble the physiologic state of T cell activation.
In contrast, anti- CD3/anti- CD28 stimulation used in our 
study activated T cells in vitro by providing both primary TCR 
signal and secondary costimulatory signal. Our findings prove 
that in contrast to CD4+ T cells, CD8+ T cells activated with 
anti- CD3/anti- CD28 ex vivo did not produce measurable 
amounts of IL- 17A. Of note, both CD4+ and CD8+ T cells were 
positive for IL- 17A during intracellular staining. Further, in a study 
by Raychaudhuri et al, anti- CD3/anti- CD28 activation for 3 days, 
instead of PMA and ionomycin, was used during intracellular 
staining, and it was found that levels of IL- 17A+CD8+ T cells 
were negligible in PsA SF compared to distinct IL- 17A+CD4+ 
T cell staining (10). However, in Raychaudhuri and colleagues’ 
study, mixed T cell subsets were activated simultaneously, and 
the possibility of IL- 17A endocytosis cannot be excluded. We 
avoided this limitation by sorting CD4+ and CD8+ T cells from 
PsA SF, and thus clearly showed that CD4+ T cells, but not 
CD8+ T cells, secrete IL- 17A upon ex vivo anti- CD3/anti- CD28 
activation. This indicated that in joints affected with PsA, TCR 
activation promotes CD4+ T cells, but not CD8+ T cells, to pro-
duce IL- 17A.
Similar results were observed for IL- 17F (Supplementary 
Figure 3, available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41271/ abstract), 
and it implies that CD4+ T cells may be the dominant source 
of both IL- 17A and IL- 17F in PsA SF upon TCR activation. In a 
recent study by Glatt et al, a dual specific antibody targeting both 
IL- 17A and IL- 17F was tested in PsA and the results supported 
the notion that neutralizing both IL- 17A and IL- 17F could achieve 
rapid and sustained therapeutic effects (30). Group 3 ILCs were 
another cell type that has been reported as a potential source 
of IL- 17A in PsA SF (15). However, a recent study showed that 
although these group 3 ILCs are expanded in inflamed arthritis 
joints, they have failed to express IL- 17A upon in vitro stimulation 
(16). These findings are similar to our observations with regard to 
CD8+ T cells. Therefore, in contrast to CD4+ T cells, the contri-
bution of CD8+ T cells and group 3 ILCs to IL- 17 production in 
PsA joints may be limited under physiologic conditions.
Biologic agents targeting IL- 17A or TNF have been proven 
effective in treating PsA patients, but clinical response rates 
vary considerably. Failed treatment with 1 biologic drug would 
necessitate the need to switch to an alternative, which can be 
a different biologic from the same class or a biologic with a 
different mode of action. We used an ex vivo human model of PsA 
synovitis to explain differential effects and showed that although 
both biologic agents efficiently inhibited the proinflammatory 
loop in the coculture system, distinct strengths existed between 
anti–IL- 17A and anti- TNF treatment. We provided evidence that 
neutralizing IL- 17A strongly reduced the level of inflammatory 
cytokines, such as IL- 6 and IL- 1β, while anti- TNF therapy was 
potent in reducing MMPs, like MMP- 3 and MMP- 13. Therefore, 
in order to achieve better and sustainable treatment results, it 
is rational to target both IL- 17A and TNF. A bispecific antibody, 
ABT- 122, was recently developed, and its first phase II study in 
PsA showed that dual inhibition had efficacy and safety simi-
lar to adalimumab, a TNF blocker (31,32). Synergistic effects of 
anti–IL- 17A and anti- TNF therapies were also observed in our 
experiments and by other investigators (33). Combination ther-
apy or sequential therapy using both neutralizing agents may be 
another option in treating PsA. However, adverse effects such 
as infection should be closely monitored during all dual neutral-
ization strategies.
Compared to IL- 17A, the percentages of IFNγ+ CD4+ and 
CD8+ T cells are relatively high in the blood of patients with PsA. 
Additionally, levels of IFNγ were much higher compared to IL- 
17A and TNF in the ex vivo human model of PsA synovitis. How-
ever, neutralization of IL- 17A or TNF did not influence the level of 
IFNγ in these coculture experiments, but significantly decreased 
inflammation in our model of PsA synovitis, indicating that 
IFNγ does not play a major role in T cell–PsA synovial fibroblast 
activation.
In PsA SF, we found a lower percentages of CD19+ B cells, 
but a higher percentage of CD56bright NK cells, which is consist-
ent with data from other groups (34–36). B cells tend to function 
in a protective way in psoriasis or PsA and can be a source of 
antiinflammatory cytokines, such as IL- 10 (35,37). Interestingly, an 
increased level of CD56bright NK cell cells was reported to trigger 
differentiation of monocytes into dendritic cells in PsA SF (38). 
Monocytes and dendritic cells are major sources of IL- 23, and 
the IL- 23/IL- 17 axis plays a pivotal role in inflammatory arthritis 
(39,40). Biologic agents targeting the IL- 23 subunits p40 and p19 
were shown to be a successful treatment strategy in PsA clini-
cal trials (41,42). Whether SF CD56bright NK cells modulate IL- 23 
expression by monocytes/dendritic cells, thereby influencing the 
IL- 23/IL- 17 axis, is still not known and warrants further research.
In summary, our study shows that the contribution of CD8+ 
T cells to the local production of IL- 17A in PsA SF needs further 
examination as TCR activation, mimicked by anti- CD3/anti- CD28 
stimulation, did not induce the secretion of IL- 17A from CD8+ 
T cells, in contrast to CD4+ T cells. IL- 17A and TNF blockade 
showed differential effects in our ex vivo human model of PsA 
synovial inflammation, with IL- 17A strongly inhibiting inflammatory 
cytokines and TNF blockade having a more potent response in 
reducing MMPs. We acknowledged the limitations of our ex vivo 
study systems, and further validation of combination therapy or 
sequential therapy in patients with IL- 17A and TNF neutralizing 
agents is needed. Our study demonstrates that targeting both 
IL- 17A and TNF may be a complementary therapeutic strategy 
that confers additive benefits in coping with destructive synovitis 
in patients with PsA.
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